Repligen (RGEN) PT Raised to $165 at Jefferies

Jefferies analyst Matthew Stanton raised the price target on Repligen (NASDAQ: RGEN) to $165.00 (from $160.00) while maintaining a Hold rating.

The analyst comments "With stock off ~15% since the Sartorius print a few weeks ago, a solid 4Q showing, '25 guide slightly ahead and largely upbeat order commentary was plenty for shares to move higher. Focus now shifts to slew of differentiated growth drivers for '25 and several new product intros which are key to driving upside to numbers moving through the year, in our view. Growth spread vs peers (~5% in '25) as market normalizes important for premium multiple."

You May Also Be Interested In

• Chemours reaches $450M settlement over PFAS pollution at four sites
• Barrington Research Starts CBIZ, Inc. (CBZ) at Outperform
• Crude Inventory Fell 6.1 Million Barrels Last Week, Says EIA